Dopamine supersensitivity psychosis
Hypothesis linking antipsychotic use to worsening psychosis via dopamine sensitivity.
Dopamine supersensitivity psychosis is a hypothesis that attempts to explain why some individuals experience worsening psychotic symptoms—such as hallucinations and delusions—despite treatment with escalating doses of antipsychotics. The theory proposes that long-term use of antipsychotics, which block dopamine D2 receptors, may lead to compensatory changes in the brain, including upregulation of these receptors, making neurons more sensitive to dopamine. This increased sensitivity may paradoxically reduce the effectiveness of antipsychotics and contribute to relapse or worsening psychosis.
- Field
- Psychiatry, Neuroscience
- Known for
- Hypothesis explaining antipsychotic-resistant psychosis and tardive dyskinesia
- First described
- 1978
- Alternative name
- Tardive psychosis
Lore & Background
The concept of dopamine supersensitivity psychosis emerged in 1978, with a featured concern being increasing resistance to medication, requiring higher doses or not responding to higher doses. Some articles use the term 'tardive psychosis' to reference this specific concept, though its validity has been disputed. The condition is not rare and has been identified in a substantial proportion of patients; Palmstierna asserts that tardive psychosis is a combination of several different and not necessarily correlated phenomena related to neuroleptic treatment of schizophrenia.
The mechanism is thought to involve upregulation of dopamine D2 receptors in response to chronic antipsychotic blockade. While studies show about a 3-fold increase in sensitivity to dopamine in people taking antipsychotics chronically, the actual increase in D2 receptor numbers is only about 1.4-fold in the striatum of people with schizophrenia, suggesting other factors such as changes in the proportion of active (D2High) versus inactive (D2Low) receptor conformations may also play a role. Tardive dyskinesia, a common movement disorder caused by antipsychotics, may also result from dopamine receptor sensitization, which could explain why increasing the antipsychotic dose temporarily improves symptoms and why abrupt discontinuation can cause withdrawal-emergent dyskinesia.
Reader's Guide
Dopamine supersensitivity psychosis represents a significant challenge in the long-term management of psychotic disorders, as it may explain why some patients require escalating doses of antipsychotics or experience relapse despite adherence. The hypothesis has implications for clinical practice: recognizing its possible role in a psychotic episode can guide how to best manage antipsychotic therapy, such as avoiding abrupt dose reductions or switches. However, the validity of the concept remains disputed in the medical literature, and it is often dismissed as an inconsequential factor by some psychiatrists. The condition is difficult to distinguish from naturally occurring psychosis in the course of a primary psychotic disorder, especially when medication nonadherence is involved. As of 2017, much of the evidence comes from animal studies, and robust human research is still needed. A cohort study found that 39% of people with schizophrenia or schizoaffective disorder who relapsed without clear cause met criteria for dopamine supersensitivity psychosis, and these individuals had worse outcomes at 6-month follow-ups. The hypothesis has also been discussed in popular media, including Robert Whitaker's 2010 book 'Anatomy of an Epidemic.'
Did You Know?
- Tardive dyskinesia, a common movement disorder caused by antipsychotics, may also be due to dopamine receptor sensitization, and increasing the antipsychotic dose can temporarily improve its symptoms.
- In a cohort study of people with schizophrenia or schizoaffective disorder who relapsed without clear cause, 39% met criteria for dopamine supersensitivity psychosis and had worse health outcomes at 6-month follow-ups.
- The dopamine supersensitivity hypothesis was discussed by investigative journalist Robert Whitaker in his 2010 book 'Anatomy of an Epidemic.'
Frequently Asked Questions
What is Dopamine supersensitivity psychosis?
It is a neurobiological hypothesis from the late 1970s proposing that chronic antipsychotic use drives the brain to multiply and hyper-sensitize dopamine D2 receptors as a compensatory response. This overcompensation is thought to explain why some patients paradoxically see their hallucinations and delusions worsen even as their medication doses climb.
Who first described Dopamine supersensitivity psychosis and when?
The concept was first articulated in 1978 within the intersecting fields of psychiatry and neuroscience. It arose from clinicians' frustration with patients on long-term antipsychotic regimens who were deteriorating rather than stabilizing.
What symptoms are most commonly linked to Dopamine supersensitivity psychosis?
The hallmark features include a resurgence or intensification of hallucinations and delusional thinking despite escalating drug dosing. The hypothesis has also been invoked to account for tardive dyskinesia, the involuntary movement disorder observed in some chronically medicated patients.
How does Dopamine supersensitivity psychosis differ from ordinary treatment-resistant psychosis?
Rather than reflecting an inherent biological insensitivity to antipsychotics, this model points to the medication itself as the trigger for the receptor-level changes. In that sense, the treatment is proposed to generate the very condition it was intended to suppress.
Why is Dopamine supersensitivity psychosis considered important in psychiatry?
It gave clinicians a mechanistic framework for understanding relapse and tardive dyskinesia in long-term antipsychotic users. Although it remains a hypothesis rather than a confirmed diagnosis, it has shaped ongoing debates about medication duration, receptor biology, and the risks of chronic dopamine blockade.
More in Psychopathological syndromes 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced